Sarah Grimwood is Vice President and Head of Scientific Services & Operations for Pfizer Ignite, an organization within the Pfizer Business Innovation Office.
Sarah’s prior role at Pfizer was Head of Portfolio, Strategy & Operations for Pfizer’s Rare Disease Research Unit (RDRU), in which she was responsible for overseeing RDRU Portfolio progression up to Phase 2 Clinical Proof of Concept. Sarah also has >25 years of Neuroscience drug discovery experience from Merck and Pfizer. She has led multi-disciplinary laboratories and numerous cross-functional teams, including portfolio project teams from Exploratory to Phase 2 stages. Sarah served on a National Institute of Health Drug Discovery for Aging, Neuropsychiatric and Neurologic Disorders, Small Business Review Panel, and oversaw Pfizer contributions to the Innovative Medicines Initiative (IMI) NEWMEDS (New Methods leading to New Medications in Depression and Schizophrenia) consortium.
Sarah obtained her PhD in Pharmacology in the UK from the University of Hertfordshire and has published >60 peer-reviewed articles.